DVA (DaVita) Moat Score : 6/10 (As of Jul. 01, 2025)

View and export this data going back to 1995. Start your Free Trial

What is DaVita Moat Score?

DaVita has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

DaVita has Narrow Moat: DaVita has a strong position in the dialysis market with significant market share and customer loyalty. It benefits from economies of scale and regulatory barriers in the healthcare sector. However, competition and potential regulatory changes limit its moat to a strong narrow category.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes DaVita might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Competitive Comparison of DaVita's Moat Score

For the Medical Care Facilities subindustry, DaVita's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DaVita's Moat Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DaVita's Moat Score distribution charts can be found below:

* The bar in red indicates where DaVita's Moat Score falls into.

Save Embed

;

Save Embed

;

DaVita (NYSE:DVA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score	Moat Level
10	Wide Moat - Exceptionally dominant and durable wide moat
8 - 9	Wide Moat - Clear and robust wide moat
7	Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6	Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5	Narrow Moat - Solid narrow moat
4	Narrow Moat - Discernible but modest moat
1 - 3	No Moat - Very weak/transient advantages
0	No Moat - No discernible moat

DaVita Moat Score Related Terms

Thank you for viewing the detailed overview of DaVita's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

DaVita Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (NYSE:DVA) » Definitions » Moat Score

Comparable Companies

Traded in Other Exchanges

0I7E:UK TRL:Germany TRL:Germany DVAI34:Brazil

Address

2000 16th Street, Denver, CO, USA, 80202

Website

https://www.davita.com

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

Executives

Berkshire Hathaway Inc	10 percent owner	3555 FARNAM STREET, OMAHA NE 68131
Javier Rodriguez	officer: Chief Executive Officer, DKC	601 HAWAII ST., EL SEGUNDO CA 90245
Joel Ackerman	officer: Chief Financial Officer	COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Michael David Staffieri	officer: Chief Operating Officer, DKC	2000 16TH STREET, DENVER CO 80202
Kathleen Alyce Waters	officer: Chief Legal Officer	C/O DAVITA INC., 2000 16TH STREET, DENVER CO 80202
Barbara J Desoer	director	CITIGROUP INC., 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
James O Hearty	officer: Chief Compliance Officer	2000 16TH STREET, DENVER CO 80202
Christopher Michael Berry	officer: Chief Accounting Officer	C/O SONDER HOLDINGS INC., 101 15TH ST., SAN FRANCISCO CA 94103
Wendy Lee Schoppert	director	6105 TRENTON LANE NORTH, MINNEAPOLIS MN 55442
Phyllis R Yale	director
Charles Berg	director, officer: Executive Chair, DMG	48 MONROE TURNPIKE, TRUMBULL CT 06611
John M Nehra	director	1119 ST PAUL ST, BALTIMORE MD 21202
Adam H Schechter	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Jason M. Hollar	director	3333 BEVERLY ROAD, HOFFMAN ESTATES IL 60179
Paula A Price	director	ONE CVS DRIVE, WOONSOCKET RI 02895